After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Patients with cutaneous lupus erythematosus who used hydroxychloroquine had a significantly reduced risk of developing systemic lupus erythematosus.

Lupus Alert Day serves a vital purpose. It encourages others to learn more about lupus, share information on social media, ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

as well as trials in cutaneous lupus erythematosus and myositis. New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up ...

Systemic Lupus Erythematosus (about 70% of cases are systemic); Discoid Lupus Cutaneous, which is limited to the skin; and Drug Induced Lupus, which occurs most commonly with drugs used to treat ...

The Lupus Foundation of America describes lupus as a chronic disease that attacks the immune system, the part of the body ...

Pericarditis recurrence in lupus is more likely — and has a dose-dependent relationship — with oral prednisone treatment, ...

A 2022 study found that just over 27% of people with systemic lupus erythematosus experience hearing loss, with 80% of cases being sensorineural hearing loss. This type of hearing loss usually ...